Indicated for the treatment of major depressive disorders in adults.
Has selected serotonin reuptake inhibitor plus post synaptic serotonin receptor partial effects, so it is regarded as a serotonin partial agonist-reuptake inhibitor.
Has a more rapid onset of effect than other anti-depressants.
Must not be used concomitantly with MAOIs due to the risk of drug interactions with serotonergic drugs.
Most frequent adverse reactions are diarrhea, 28%, nausea 23%, insomnia 6% and vomiting 5%, dizziness, headache, and dry mouth.
Associated with insomnia.
Associated with low incidence of sexual dysfunction.
Tablets-10, 20, and 40 mg.
Should be initiated at 10 mg per day and doubled every seven days to target of 40 mg per day.
When used in combination with a strong CYP3A inhibitor dose adjustment to 20 mg a day is recommended.
No dose adjustment is required for mild to moderate renal or hepatic impairment.